Hiberna

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hiberna

Quick Facts

Property Description
Active Ingredient Promethazine hydrochloride
Primary Class First-generation antihistamine
Composition Single-ingredient product
Common Forms Tablet, syrup, suppository, injection
Origin Type Synthetic (Phenothiazine derivative)

What Type of Medication is Hiberna? (Identity and Classification)

Hiberna is the trade name for the medication containing the active ingredient Promethazine hydrochloride. This is a synthetic compound classified primarily as a first-generation antihistamine, belonging to the larger chemical group of phenothiazine derivatives.

The specific chemical structure of Promethazine allows it to act upon the central nervous system significantly, distinguishing it from newer, less-sedating antihistamine classes. The substance exhibits potent anticholinergic properties alongside its primary H1 receptor action. Its high sedative potential, a property clinically recognized for decades of use in medicine, differentiates it from non-sedating alternatives, positioning Hiberna for cases where pronounced calming and rest are key therapeutic goals.


Composition and Available Forms of Promethazine

The product is defined as a single-ingredient product, utilizing only Promethazine hydrochloride as the core therapeutic agent. This active substance is combined with excipients or an aqueous/syrup vehicle to create the final pharmaceutical preparation.

Promethazine is highly versatile in its presentation, ensuring accessibility for patients across varied needs. Common pharmaceutical preparations include oral dosage forms like tablets and syrup, as well as specialized routes such as rectal suppositories and solutions for intramuscular injection. This flexibility in administration route allows for its continued use even when oral intake is compromised, for example, during severe episodes of nausea and vomiting.


General Purpose and High-Level Action

The general purpose of Hiberna is to provide relief by modulating key chemical signals in the body that cause symptoms in three main areas: allergic conditions, motion sickness, and the urge to vomit. The drug provides its anti-allergic effect by acting as an H1-receptor antagonist, blocking the action of histamine.

Its secondary actions, including its anticholinergic and mild antidopaminergic properties, are crucial for its other general uses. Promethazine is noted for its powerful sedative and antiemetic (anti-vomiting) effects. These effects mean the drug is frequently used to calm the body and reliably alleviate nausea, vomiting, and discomfort from motion sickness, such as when traveling.

Regulatory References

  1. NIH StatPearls summary
  2. MedlinePlus Drug Information

What side effects are possible with Hiberna?

Possible Side Effects and Safety Information

The official safety profile for Hiberna (Promethazine hydrochloride) is characterized by effects on the central nervous system (CNS) and its anticholinergic properties, which are inherent to its classification as a first-generation antihistamine.

Adverse Reaction Scope

Classification Representative Reactions
Common Sedation (somnolence, drowsiness), dizziness, dry mouth, blurred vision, constipation, nausea, and vomiting.
Infrequent/Rare Neuroleptic Malignant Syndrome (NMS), bone marrow depression (e.g., agranulocytosis), jaundice, and photosensitivity.

The systems primarily involved include the Nervous System (sedation, NMS, seizures), Respiratory System (respiratory depression), Blood and Lymphatic System (leukopenia), and Gastrointestinal System (dry mouth, constipation).

Serious and Systemic Safety Concerns

The medication is associated with several serious adverse reactions documented in regulatory sources:

  • Fatal Respiratory Depression: Noted as a primary safety risk, particularly in infants.
  • Neuroleptic Malignant Syndrome (NMS): A rare, potentially fatal complex characterized by symptoms such as severe fever and muscle rigidity.
  • Severe Tissue Injury, Necrosis, and Gangrene: Associated with the injection form.
  • Bone Marrow Depression: Including serious conditions like agranulocytosis.

Population-Specific Safety Constraints

The label defines specific safety constraints for certain groups, with the most stringent being the absolute contraindication for use in children less than two years of age due to the potential for fatal respiratory depression. Caution is also advised for older adults due to increased sensitivity to sedation, confusion, and the risk of postural hypotension. Patients with impaired liver or kidney function may require close monitoring during prolonged use.

Safety-Related Restrictions

The risk of respiratory depression warrants close monitoring during the initiation of therapy. The medication is generally restricted for use in patients with pre-existing conditions that can be worsened by its anticholinergic properties, such as narrow-angle glaucoma or prostatic hypertrophy, or by CNS depression. The official safety structure highlights the necessity of these constraints to define the appropriate boundaries for use.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical advice must be sought in the event of any suspected overdose. Contact your local emergency number or Poison Help line immediately as overdose carries the potential for severe or life-threatening outcomes, as documented in regulatory information.

Officially documented manifestations of overdose primarily involve central and autonomic nervous system toxicity. These can include states of profound CNS depression, such as coma and severe drowsiness, or CNS excitation, which may present as agitation, hallucinations, seizures, and hyperreflexia. Anticholinergic signs, such as dilated pupils, dry mouth, and urinary retention, are also recognized features.

Severe consequences noted in regulatory documents include severe respiratory depression, cardiac arrhythmias (including QT prolongation), and the potential for sudden death. Overdose in pediatric patients is explicitly associated with an increased risk of these severe outcomes, with infants under 2 years being highly susceptible to fatal respiratory depression. Elderly patients may also show increased sensitivity leading to greater confusion.

Treatment is officially defined as symptomatic and supportive, as no specific antidote is known. Procedures focus on continuous monitoring, especially of vital signs and cardiac function (ECG), alongside essential airway support. Regulators specifically warn that Epinephrine should not be used to treat hypotension associated with this type of overdose.

Therapeutic Uses of Hiberna

Hiberna (Promethazine) is generally used to provide symptomatic relief applied across domains where additional symptomatic support is needed when patients experience symptoms related to heightened physiological activity or systemic imbalance. It is commonly used when short-term symptomatic assistance is needed to manage disruptive manifestations.

The medication is applicable in addressing conditions characterized by periods of heightened symptoms, including allergic rhinitis (hay fever), uncomplicated urticaria (hives) or other allergic skin reactions, motion sickness, and nausea/vomiting associated with surgery or other procedures. For example, it helps address symptom clusters that may become intense or disruptive, such as persistent itching, sneezing, and ocular irritation.

Therapeutic Domains and Patient Comfort

For acute scenarios like postoperative recovery or travel, the medication is applied to manage distressing symptoms like nausea and vomiting, supporting patients during episodes of heightened discomfort. Furthermore, it is relevant when supportive symptom management is appropriate to ease apprehension and restlessness, contributing to improved comfort during periods of heightened symptoms by supporting rest.


Quick Fact: Symptomatic Relief Domains Description
Allergy Symptoms Helps with intense itching, sneezing, and allergic skin discomfort.
Gastrointestinal Distress Used for managing nausea and vomiting in acute settings.
Nervous System Applied to ease apprehension and is relevant for easing distress.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Status for Hiberna (Promethazine HCl)

The criteria for using Hiberna are strictly defined by regulatory documents, establishing populations who are eligible, restricted, or absolutely prohibited from use.

Category Regulatory Status
Absolute Contraindication Pediatric patients less than two years of age must not use this medicine due to the severe risk of fatal respiratory depression. Contraindicated for patients in comatose states or with known hypersensitivity to phenothiazines.
Age-Related Restrictions Use in children two years of age and older requires caution and the lowest effective dose. Some international labels contraindicate oral forms for children under six years. Older adults may be more susceptible to side effects like confusion and sedation.
Conditional Use (Caution) Use must proceed with caution in individuals with conditions such as seizure disorders, bone-marrow depression, or severe renal or hepatic impairment. The drug is contraindicated for treating lower respiratory tract symptoms, including asthma.
Pregnancy/Lactation Use near the time of delivery is not recommended. Use during lactation is generally not recommended.

Eligibility is conditional on specific health factors. The medicine is also contraindicated if administered via intra-arterial or subcutaneous injection.

What should I know about interactions with other medicines?

The official regulatory profile for Hiberna is defined by two primary interaction classifications: Contraindicated Combinations and Clinically Significant Pharmacodynamic Reinforcement. These classifications establish mandatory restrictions for co-administration.

Interaction Scope Description
Medicinal Product Categories CNS depressants, Monoamine Oxidase Inhibitors (MAOIs), Anticholinergic Agents, Sympathomimetic Agents (e.g., Adrenaline/Epinephrine), CYP2D6 Inhibitors, and Ototoxic Medications.
Timing-based Rules Metrizamide: Discontinuation is required at least 48 hours before administration. Allergen Skin Tests: Antihistamine effects may produce false-negative results and require the drug to be discontinued at least 72 hours prior.

Official Interaction Statements:

  • Co-administration with MAOIs is contraindicated, as it prolongs and intensifies both the CNS depressant and anticholinergic effects.
  • The drug may significantly potentiate the sedative action of all CNS depressants, including alcohol. This is an additive effect.
  • Interaction with CYP2D6 inhibitors, such as certain beta blockers, may result in increased plasma concentrations of both agents due to documented inhibition of metabolism.
  • The alpha adrenoceptor effects of Adrenaline (epinephrine) may be blocked, potentially causing severe hypotension if co-administered.
  • Use is contraindicated in pediatric patients under two years of age due to the risk of potentially fatal respiratory depression, and caution is required with other respiratory depressants in patients ge 2 years.

Connection to the overall interaction profile: The profile is structured around pronounced pharmacodynamic potentiation and specific metabolic pathways, emphasizing restrictions on substances that increase CNS depression or antagonize adrenergic effects. These statements define mandatory constraints and prohibitions established by regulatory authorities.

Mechanism of Action

Multi-Receptor Neurotransmitter Blockade

The fundamental mechanism of Hiberna involves acting as a non-selective antagonist across three primary neurotransmitter receptor systems: the histamine H1 receptors ( H1 R), muscarinic acetylcholine receptors ( mAChR), and mild antagonism of dopamine D2 receptors ( D2 R). This simultaneous interaction with multiple, distinct biological targets defines the molecule's unique pharmacological range, resulting in simultaneous inhibition of pathways associated with arousal and reflex control.


Central Nervous System Pathway Suppression

Due to its high ability to cross the blood-brain barrier, the drug directly influences central arousal and emetic (vomiting) control pathways. Blockade of H1 R in the brain's Tuberomammillary Nucleus (TMN) suppresses the histaminergic system responsible for wakefulness, resulting in significant central nervous system deactivation. Additionally, antagonism of both mAChR and D2 R within the Chemoreceptor Trigger Zone (CTZ) interrupts afferent signals from the vestibular system and viscera, interrupting emetic signal transmission within the control center.


Auxiliary Mechanisms and Functional Constraints

A secondary, non-receptor mechanism involves the inhibition of voltage-gated sodium ( Na^+) channels at high local concentrations, which prevents the propagation of nerve impulses in peripheral sensory pathways. This auxiliary action is independent of the primary receptor blockade. The non-selective activity across H1 R and mAChR results in a broader pharmacological profile, where the activity on the cholinergic system influences the overall physiological consequence.

Dosage and Administration Information

How Hiberna is Used: Official Administration Guidelines

The administration of Hiberna (Promethazine hydrochloride) follows standardized protocols to ensure proper use. This guidance details the officially approved routes, dosing schedules, and preparation requirements as established in the drug's label.

Approved Administration Routes and Forms

Hiberna is available in several forms, which dictate the official routes of administration. These include oral dosage forms (tablets and syrup), rectal suppositories, and solutions for injection. The preferred injection method is deep Intramuscular (IM). The Intravenous (IV) route is permissible but generally reserved for specific conditions and requires strict procedural controls.

Official Dosing and Frequency Patterns

Dosing is primarily based on the patient's symptomatic needs and is intended for short-term assistance. The regimen typically uses the lowest effective amount.

Indication Standard Adult Labeled Dose Range Frequency
Allergic Symptoms 12.5 mg to 25 mg Once daily at bedtime OR up to three times daily.
Nausea and Vomiting 12.5 mg to 25 mg (Oral, Rectal, or IM) Every 4 to 6 hours as needed.
Motion Sickness 25 mg Taken 30 minutes to 1 hour before travel; may be repeated 8 to 12 hours later.
Sedation 25 mg to 50 mg (Single dose) Given at bedtime or pre-procedure.

Key Administration Procedures and Restrictions

Oral doses may be taken with food, water, or milk to help reduce gastric irritation. For accurate liquid dosing, an official measuring device must be used instead of a household spoon. When the IV route is selected, the medication must be diluted and injected slowly at a rate not exceeding 25 mg per minute through a large, patent vein to mitigate risks. Officially, the use of Hiberna is contraindicated for children under 2 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hiberna

Evidence for Use in Postoperative Nausea and Vomiting (PONV)

Research for Hiberna (Promethazine) was conducted to explore its use for acute nausea and vomiting following surgery. This research relies primarily on randomized controlled trials (RCTs) and comprehensive meta-analyses. Studies monitored outcomes related to physical discomfort, specifically the frequency of vomiting episodes and patient-reported discomfort from nausea during the immediate recovery phase. Studies conducted shortly after operations reported measurements of nausea and vomiting compared to placebo.

A key finding monitored in these studies was the simultaneous measurement of postoperative sedation levels, which often differed significantly from groups receiving placebo. Data on the overall impact of associated drowsiness on the patient's time to readiness for hospital discharge remain limited or consistently documented.

Evidence for Use in Allergic Conditions

Hiberna was studied for conditions involving periods of heightened symptoms, such as allergic rhinitis (hay fever) and hives (urticaria). The evidence base is supported by older clinical trials and regulatory reviews of available data. Research examined outcomes linked to irritative states, focusing on symptoms like persistent itching, sneezing, and ocular irritation.

Findings describe patterns observed in the studies where outcomes related to systemic or functional imbalance were monitored. Research highlights that the measurement of sedative properties is a common outcome in these studies, where evidence is limited for extended use. Long-term effects are not fully established when using this type of medication for chronic or recurrent allergic conditions.

Research Gaps and Remaining Uncertainties

One key research limitation is the sedative effect; it is a primary characteristic of the medication and acts as a limiting factor in comparative studies against newer agents that lack this specific outcome. Comparative evidence is lacking for many long-term or chronic uses, as the focus of modern research has shifted. Furthermore, sample sizes were modest in some older trials, and the evidence quality varies across studies due to the drug’s long history of use. The findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Anti-emetic Drugs for Prophylaxis of Postoperative Nausea and Vomiting After Craniotomy: An Updated Systematic Review and Network Meta-Analysis
  2. Promethazine - StatPearls [Used for allergic conditions and general background]
  3. Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis [Used for comparative context on sedating antihistamines]
  4. The Pharmacologic Management of Motion Sickness [Review covering Promethazine trials and comparative efficacy]
  5. The Effects of Promethazine on Human Performance, Mood States, and Motion Sickness Tolerance [Controlled study in specialized settings]
  6. Antihistamines and allergy - Australian Prescriber (Used for general context on first-generation agents and sedation)

Frequently Asked Questions (FAQ)

Common questions about Hiberna (FAQ)


Q: How quickly does Hiberna usually start to have an effect?

A: Official product information on Hiberna notes that after a person takes an oral dose, the drug is absorbed through the digestive system. Official information indicates that effects can begin within approximately 20 minutes following oral use, or more quickly following injection. Actual time of onset can vary by individual.


Q: Is it true that Hiberna can cause drowsiness?

A: Regulatory safety documents list sedation (which includes drowsiness or somnolence) as a common adverse reaction. This effect is a common outcome, described as being related to the drug’s action as a first-generation antihistamine.


Q: Can someone stop using Hiberna abruptly?

A: Patient information for Hiberna notes that if the drug has been taken for a prolonged time and is then stopped suddenly, some people may experience symptoms like dizziness, sweating, or difficulty sleeping. In general contexts, gradual discontinuation is sometimes described as a way to minimize these effects, but specific guidance for stopping use should be sought from a healthcare professional.


Q: Is it required to have a special blood test before starting Hiberna?

A: Official warnings mention that caution is needed for people who have certain pre-existing conditions, such as bone-marrow depression or severe kidney or liver impairment. While the label does not explicitly mandate a pre-treatment blood test, caution is advised and monitoring may be necessary when underlying conditions, such as those that affect the body's blood cell production or organ function, are present.


Q: Does using Hiberna change how the body processes alcohol?

A: Official drug interaction statements caution that Hiberna may increase or intensify the sedative effect of all Central Nervous System (CNS) depressants, which includes alcohol. This is an additive effect that may make the combined sedative effects more pronounced.


Q: Is it typical to feel a little dizzy when first starting Hiberna?

A: Dizziness is a reaction that is described in official documentation as a common side effect. The potential for common side effects like dizziness and drowsiness may be more noticeable at the initiation of therapy.


Q: Can Hiberna affect sleep patterns?

A: Hiberna can affect sleep. The drug is officially used for its sedative effects, and is indicated as a bedtime aid. This action is achieved by influencing the central nervous system pathways, including blocking receptors in the brain to suppress the system associated with wakefulness.


Q: Is the dosage often adjusted after starting Hiberna?

A: Official guidance emphasizes that dosing for Hiberna is intended to be flexible, based on a patient's symptomatic needs, and uses the lowest effective amount. This approach suggests that the dosage may be subject to adjustment or tailoring to individual requirements over time.


Q: Can Hiberna cause sensitivity to sunlight?

A: Official safety information reports photosensitivity (which means increased sensitivity to sunlight) as an infrequent or rare adverse reaction. If you are using this medication, general caution regarding sun exposure is warranted.


Q: What is the meaning of the 'half-life' of Hiberna?

A: The half-life refers to the measure of time it takes for the concentration of the drug in the blood to decrease by half. For Hiberna, the reported elimination half-life is typically between 10 to 19 hours, which provides context for the duration of its presence in the body.


Q: Can I continue to use caffeine while taking Hiberna?

A: Official interaction statements warn against the use of Central Nervous System (CNS) stimulants. Hiberna’s sedative effects may counteract or antagonize the stimulating effects of substances like caffeine, due to opposing actions on brain activity.


Q: Does Hiberna have an effect on driving or operating machinery?

A: Official warnings indicate that due to its effects, the medication may influence the mental and physical abilities required for performing certain tasks. This includes activities that require high levels of alertness, such as driving a vehicle or safely operating complex machinery.


Q: Are there any major medications that cannot be mixed with Hiberna?

A: Official regulatory documents list several major classes of medicines that should not be combined with Hiberna due to potential risks. These include MAOIs, potent CNS depressants, and Adrenaline (epinephrine), which Hiberna has the potential to block. The full list of major classes is available in the official prescribing information.


Q: Does body weight or BMI influence the effects of Hiberna?

A: While dosing for adults is primarily based on symptoms, official regulatory guidance for pediatric use sometimes requires a weight-based calculation (mg/kg) to determine the appropriate amount. This indicates that body mass is a factor considered during the administration of the drug.


Q: Is Hiberna approved for use in teenagers?

A: Official documents contain warnings and specific restrictions for children two years of age and older, with an absolute contraindication for use under two years. The regulatory profile addresses pediatric use broadly, and the drug is not specifically contraindicated for the general teenager population (13–18 years).


Q: Why do people use Hiberna to help them sleep?

A: Hiberna is officially used for sedation and as a bedtime aid. Its mechanism of action includes a strong blocking effect on H1 receptors in the brain, which suppresses the signaling system responsible for wakefulness, thereby promoting a calm state.


Q: Does Hiberna work by blocking something or by increasing something?

A: Official descriptions of its mechanism of action state that Hiberna works primarily by blocking or acting as an antagonist across multiple receptor systems. This action results in the suppression of histamine and acetylcholine effects, and mild antagonism of dopamine, interrupting various biological signals.


Q: Is Hiberna considered a controlled substance?

A: Single-ingredient Hiberna (Promethazine) is generally not classified as a controlled substance by major government drug agencies. However, it is important to note that combination products that include Hiberna alongside other ingredients (such as certain cough suppressants) are classified as controlled substances.


Q: What does it mean that Hiberna is metabolized by the liver?

A: Official product information states that Hiberna is extensively metabolized by the liver. This term means the liver is the primary site where the body chemically converts the drug into other compounds, called metabolites, before it is removed from the body.

How should Hiberna be stored and disposed of?

Hiberna (Promethazine) must be stored at Controlled Room Temperature, typically 20 C to 25 C. The medicine must be protected from light, and it is strictly prohibited to freeze any formulation. It is mandatory to keep the product in its original container, tightly closed, and stored away from excess moisture.

The injectable solution should be used immediately after opening and must be discarded if it shows discoloration or precipitate. The official labeling mandates that this medicine be kept out of the sight and reach of children.

Disposal should follow official guidelines, which recommend using a medication take-back program. If this option is unavailable, the unused medicine should be mixed with an undesirable substance, sealed in a container, and discarded in the household trash to prevent misuse.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hiberna found in:

A-Z Index: